COSCIENS Biopharma Inc. announced a new corporate presentation detailing its recent acquisition of Nualtis Corp and ongoing private placement of 15% unsecured convertible debentures. The company has issued about US$12 million of debentures and aims to raise up to US$20 million by mid-November. Funds raised so far, combined with existing cash, cover a US$6 million deferred payment for Nualtis due in March 2027. If fully subscribed and converted, COSCIENS expects a pro forma market cap of around US$27 million and over US$7 million cash on hand, with no debt after the payment. The update signals strong investor interest and financial positioning ahead of a shareholder vote on debenture conversion expected in December.
COSCIENS Biopharma Inc.'s corporate update and convertible debenture offering provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Oct 19, 2026 18:01 WIB: out of 150 priced US health stocks, 73 rose and 47 fell. Notable movers include MESO at USD 12.65 (-4.74%), CTXR at USD 0.48 (+4.13%), and HRTX at USD 0.37 (+2.49%).
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
